Arvinas Secures Cash Runway to H2 2028, Eyes Multiple 2026 Data Readouts
Arvinas ended 2025 with cash runway into the second half of 2028 and submitted its first PROTAC new drug application. The company appointed Randy Teel as CEO and plans Phase 1 data presentations for ARV-102 in Parkinson’s, ARV-806 in KRAS G12D cancers and ARV-393 in lymphoma during 2026.
1. Financial Results and Cash Runway
Arvinas reported fourth quarter and full year 2025 results, ending the year with sufficient funds to operate into the second half of 2028. The company also submitted its first PROTAC new drug application, positioning itself for a potential first-ever FDA approval in this modality.
2. Leadership Changes
The board appointed Randy Teel, Ph.D., as President, Chief Executive Officer and Director, succeeding John Houston, who remains on the board and as a consultant. Briggs Morrison, M.D., was elected Chair of the board to strengthen corporate governance.
3. Pipeline Milestones
Arvinas expects several key data readouts in 2026: Phase 1 ARV-102 LRRK2 degrader data at the March AP/PD conference, clinical updates for ARV-806 KRAS G12D and ARV-393 BCL6 degrader later in the year. The company also initiated a Phase 1 trial of ARV-027 in healthy volunteers and plans to start ARV-6723 HPK1 degrader Phase 1 by mid-2026.